Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis' secret...

    Novartis' secret settlement talks revealed in accidental filing: Bloomberg Report

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-13T10:03:25+05:30  |  Updated On 16 Aug 2021 3:11 PM IST

    The U.S. sued the Novartis six years ago, joining in a case filed by a former sales representative who accused the company of using its speaker's programs to pay kickbacks to doctors who prescribed its drugs.


    New Delhi: Confidential settlement talks between Novartis AG and the U.S. government over allegations that the company paid doctors to market its products are not so secret anymore.


    The U.S. sued the Swiss drugmaker six years ago, joining in a case filed by a former sales representative who accused the company of using its speaker's programs to pay kickbacks to doctors who prescribed its drugs. The case was scheduled to go to trial before U.S. District Judge Paul Gardephe in Manhattan on May 20 when it was delayed indefinitely without a reason.


    On Tuesday, a letter inadvertently made public said the parties had made " significant progress" on reaching a deal. The letter, written to Gardephe by lawyers for U.S. Attorney Geoffrey Berman, was filed in the court docket and then removed a short time later by the judge's staff.


    Read Also: Novartis gets new pharma chief Marie-France Tschudin; bids farewell to Paul Hudson

    The letter confirmed that there is a " monetary aspect" of the settlement that has been submitted to the Justice Department for expedited approval. It also revealed that the company is negotiating a new corporate integrity agreement with the inspector general for the Health and Human Services Department that would require it to improve efforts to comply with the law.


    Such agreements "require defendants to implement a specified set of compliance obligations including the establishment of a compliance officer and compliance infrastructure, training, a risk assessment program, and outside monitoring by an independent review organization," according to the letter.


    Under the proposed accord, the government would allow Novartis to continue to participate in federal health care programs.


    While Berman said the settlement will be " substantially complete" by June 18, the parties have until August 13 to finalize and execute it. Berman had asked that the letter not be made public in order to preserve confidentiality while talks continue.


    Read Also: Sanofi poised to appoint Novartis' Paul Hudson as CEO

    The company is accused of paying thousands of doctors with speaking fees, fishing trips and even outings at Hooters restaurants to boost sales of hypertension drugs Lotrel and Valturna, along with diabetes medication Starlix. The U.S. had once sought as much as $2 billion in damages, Bloomberg Intelligence analyst Holly Forum has estimated. Novartis may have been close to a $1 billion settlement, Stat reported on May 15, citing sources familiar with the matter.


    "Novartis confirms that we are engaged in settlement discussions with the Southern District of NY to resolve the ongoing Speaker Program litigation," spokesman Eric Althoff said in an email. "We cannot comment further at this time."


    A spokesman for Berman declined to comment.


    The case is U.S. v. Novartis, 11-cv-71, U.S. District Court, Southern District of New York (Manhattan)

    diabetesdoctorshealth carehypertensionhypertension drug Lotrelhypertension drug ValturnaJudge Paul GardepheLotrelMBBSmedicalmedical professionalsNovartisNovartis AGnovartis secret filingpharma co casepharma newsPrescription DrugsStarlixUnited StatesUSUS Attorney Geoffrey BermanValturna
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok